Hunger hormone levels in blood may reveal dementia type
NCT ID NCT05381090
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study investigates whether levels of the hormone ghrelin in the blood differ between people with various types of dementia, including Alzheimer's disease and dementia with Lewy bodies. Researchers will collect blood samples from 85 participants over age 60, both fasting and after eating, to measure ghrelin and related markers. The goal is to see if these measurements can help identify or distinguish different forms of dementia.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to help diagnose or distinguish different types of dementia earlier.
- What could go wrong
- This is a small, early-stage study that only measures biomarkers, not a treatment. The findings may not translate into a reliable diagnostic test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
85 people
The number who actually took part.
- Started
-
Aug 2022
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \> 60 years * Subject or carer / legal representative is willing to sign consent document Specific criteria for each group; Parkinson's Disease * PD diagnosed by a movement disorder specialist and meets the diagnosis of PD * MoCA \> 26/30 * No evidence of cognitive symptoms causing functional impairment Parkinson's Disease Dementia * PD diagnosed by a movement disorder specialist * Duration of motor symptoms \> 1 year * Meets MDS task force criteria for PDD * MoCA \< 21/30 Dementia with Lewy Bodies * Meets criteria for probable DLB as defined by the 4th report of the DLB consortium Alzheimer's Disease * Meets criteria for probable AD dementia (consistent with NIA/AA core clinical criteria for probable AD dementia) Exclusion Criteria: * Age \< 60 years * Current major depression * Use of anti-psychotic medication * Type I or Type II diabetes mellitus (DM) (excluding diet-controlled DM) * Tobacco use * BMI \<15.0 kg/m2 * BMI \> 30 kg/m2 * Comorbid gastrointestinal disease i.e. includes Coeliac, active Inflammatory Bowel Disease (Colitis), evidence for active gastric ulcers within the last 12 months, but excludes gastroesophageal reflux and hiatus hernia. * \>5 kg weight change over the preceding 3 months (determined by researcher from previous clinic visit and discussion with partner/carer) * Significant active comorbidity * Difficult venous access * Vagotomy Additional disease specific exclusions; * Parkinson's Disease exclusion criteria * Evidence of dementia or mild cognitive impairment * Deep brain stimulation (DBS) * Use of Duodopa Parkinson's Disease Dementia exclusion criteria * Dementia within 12 months of diagnosis of PD * DBS Dementia with Lewy bodies exclusion criteria * Onset of motor Parkinsonism symptoms greater than 12 months prior to dementia diagnosis Alzheimer's dementia exclusion criteria * Presence of PD, PDD, DLB, or Frontotemporal Dementia (FTD) Controls exclusion criteria * Evidence of parkinsonism * Evidence of dementia or mild cognitive impairment * MoCA \<26/30
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Swansea University
Swansea, sa2 8pp, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glutathione, brain metabolism and inflammation in Alzheimer's disease
- Individualized 130 hz subthalamic temporal interference stimulation versus medication for motor symptoms in parkinson disease
- Parkinson's improvement activated by hula understanding (PAHU) - part 2
- Half a million people join quest to decode Parkinson's risk
- Can a home feeding coach keep dementia patients out of the hospital?
- Can a diabetes drug slow Parkinson's? a trial puts it to the test